Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymph node staging in clinically localized prostate cancer.

C C Parker1, J Husband, D P Dearnaley

  • 1Academic Department of Radiotherapy, Royal Marsden NHS Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.

Prostate Cancer and Prostatic Diseases
|December 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to 'Letter to the Editor regarding "Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]", by C. C. Parker et al.'

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

RADICALS-HD: Reflections before the Results are Known.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Seven or less Fractions is Not the Standard of Care for Intermediate-Risk Prostate Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same journal

Focal therapy for localized prostate cancer: not all that glitters is gold.

Prostate cancer and prostatic diseases·2026
Same journal

A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care.

Prostate cancer and prostatic diseases·2026
Same journal

En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?

Prostate cancer and prostatic diseases·2026
Same journal

Response to de Riese et al. regarding "methodological and clinical considerations of MRI-based prostate cancer risk calculators".

Prostate cancer and prostatic diseases·2026
Same journal

Methodological and clinical considerations of MRI-based prostate cancer risk calculators.

Prostate cancer and prostatic diseases·2026
Same journal

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate cancer and prostatic diseases·2026
See all related articles

Pelvic lymph node involvement in prostate cancer impacts prognosis and treatment. Emerging evidence suggests some patients may benefit from radical treatments, necessitating accurate nodal status assessment.

Area of Science:

  • Urologic Oncology
  • Prostate Cancer Research
  • Surgical Pathology

Background:

  • Pelvic lymph node metastasis is a critical adverse prognostic factor in clinically localized prostate cancer.
  • Accurate assessment of nodal status is crucial for effective patient management and treatment planning.
  • Historically, nodal disease was considered incurable, but recent findings challenge this paradigm.

Purpose of the Study:

  • To review current methods for assessing pelvic lymph node status in prostate cancer.
  • To discuss the advantages and disadvantages of predictive nomograms, imaging, and surgical staging.
  • To explore future developments and optimal strategies for detecting lymph node metastases.

Main Methods:

  • Review of predictive nomograms for estimating lymph node metastasis risk.

Related Experiment Videos

  • Evaluation of imaging modalities (e.g., CT, MRI, PET) for detecting nodal involvement.
  • Discussion of surgical staging techniques, including pelvic lymph node dissection.

    • Main Results:

    • No specific results were detailed, but the abstract discusses the pros and cons of each assessment method.
    • Evidence suggests that some patients with lymph node involvement may benefit from multimodality treatment.
    • The study considers the evolving therapeutic implications of nodal disease detection.

    Conclusions:

    • Accurate detection of pelvic lymph node metastases is vital for guiding treatment decisions in prostate cancer.
    • Combining diagnostic approaches may offer optimal strategies for nodal status assessment.
    • The potential curability of some cases of nodal disease necessitates refined diagnostic and therapeutic approaches.